2-(2-cresyl)-4H-1,3,2-benzodioxaphosphorin-2-oxide, also known as **Saligenin cyclic phosphate**, is a cyclic phosphate ester derivative of saligenin.
Here's why it's important for research:
**1. Potential Anticancer Activity:**
* Saligenin cyclic phosphate has shown **promising anticancer activity** in preclinical studies.
* It acts as a **tyrosine kinase inhibitor**, interfering with the signaling pathways that drive cancer cell growth and proliferation.
* Studies suggest it may be effective against **leukemia, breast cancer, and melanoma**.
**2. Potential Antiviral Activity:**
* It exhibits **inhibitory effects against certain viruses**, including HIV and herpes simplex virus.
* This activity stems from its ability to interfere with viral replication processes.
**3. Neuroprotective Properties:**
* Research indicates that Saligenin cyclic phosphate might have **neuroprotective effects**, particularly in the context of neurodegenerative diseases like Alzheimer's.
* It may help protect neurons from damage by reducing oxidative stress and inflammation.
**4. Research Tool for Studying Phosphorylation:**
* As a cyclic phosphate, it serves as a useful **tool for investigating phosphorylation reactions**, a crucial process in cellular signaling and regulation.
* Researchers use it to study the role of phosphorylation in various biological processes.
**5. Promising Lead Compound for Drug Development:**
* Due to its potential therapeutic applications, Saligenin cyclic phosphate has emerged as a **promising lead compound for the development of new drugs**.
* Further research is ongoing to optimize its properties and explore its clinical potential.
**Important Note:** While Saligenin cyclic phosphate holds promise in various research areas, it's crucial to remember that it's still in preclinical stages of development. Further studies are needed to fully understand its safety, efficacy, and potential side effects in humans.
2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide: cyclic metabolite of tri-o-cresyl phosphate; synergist for cholinesterase inhibitors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 104993 |
| MeSH ID | M0040682 |
| Synonym |
|---|
| phosphoric acid, cyclic methylene-o-phenylene o-tolyl ester |
| 4h-1,3,2-benzodioxaphosphorin, 2-(o-tolyloxy)-, 2-oxide |
| 4h-1,3,2-benzodioxaphosphorin, 2-(2-methylphenoxy)-, 2-oxide |
| 2-(2-cresyl)-4h-1-3-2-benzodioxaphosphorin-2-oxide |
| 2-(o-cresyl)-4h-1,3,2-benzodioxaphoran-2-one |
| cbdp |
| brn 2538084 |
| 1222-87-3 |
| 2-(2-methylphenoxy)-4h-1,3,2-benzodioxaphosphorin 2-oxide |
| 2-(2-methylphenoxy)-2h,4h-1,3,2lambda~5~-benzodioxaphosphinin-2-one |
| DTXSID00924111 |
| 2-(2-methylphenoxy)-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide |
| Q26840938 |
| 2-(2-methylphenoxy)-4h-1,3,2-benzodioxaphosphorin2-oxide |
| 2-(2-methylphenoxy)-4h-1,3,2lambda5-benzodioxaphosphinine 2-oxide |
| 2-(o-tolyloxy)-4h-benzo[d][1,3,2]dioxaphosphinine 2-oxide |
| PD193843 |
| mfcd00798815 |
| SY327056 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "0 LD50 of [3H]-soman, 60 min following pretreatment with either 2-O-cresyl-4H-1:2:3 benzodioxa-phosphorine-2-oxide (CBDP), which blocks CaE or 7-(methylethoxyphosphinyloxy)-1-methyl quinolinium iodide (MEPQ), which selectively inhibits intravascular ChE." | ( Effects of CBDP and MEPQ on the toxicity and distribution of [3H]-soman in mice. Chapman, S; Cohen, G; Kadar, T; Raveh, L; Shapira, S, 1990) | 0.28 |
| " Without pretreatment, the 24-h LD50 for soman was 118." | ( Cresylbenzodioxaphosphorin oxide pretreatment alters soman-induced toxicity and inhibition of tissue cholinesterase activity of the rat. Jimmerson, VR; Mailman, RB; Maxwell, DM; Shih, TM, 1989) | 0.28 |
| "The ability of the carbamates pyridostigmine and physostigmine to protect against the lethal effects of soman, an extremely toxic anticholinesterase agent, was measured in rats, guinea pigs and rabbits." | ( Effect of carboxylesterase inhibition on carbamate protection against soman toxicity. Brecht, KM; Lenz, DE; Maxwell, DM; O'Neill, BL, 1988) | 0.27 |
| " Thus, it appears that the toxic stereoisomers of soman have a similar affinity for mouse serum carboxylic-ester hydrolase, and CBDP pretreatment does not enhance selectively the toxicity of one stereoisomer over the other." | ( Stereoisomers of soman (pinacolyl methylphosphonofluoridate): inhibition of serum carboxylic ester hydrolase and potentiation of their toxicity by CBDP (2-(2-methylphenoxy)-4H-1,3,2-benzodioxaphosphorin-2-oxide) in mice. Benschop, HP; Clement, JG; DeJong, LP; Wolthuis, OL, 1987) | 0.27 |
| " This CBDP treatment also reduced the subcutaneous soman LD50 in these species by 48-90% in comparison to the soman LD50 in control animals." | ( The effect of carboxylesterase inhibition on interspecies differences in soman toxicity. Brecht, KM; Maxwell, DM; O'Neill, BL, 1987) | 0.27 |
| " The animals tolerated an accumulated 6-fold LD50 dose and survived an LD90 dose of carbachol, indicating tolerance to this cholinergic agonist." | ( Different role of carboxylesterases in toxicity and tolerance to paraoxon and DFP. Dettbarn, WD; Milatovic, D; Yang, ZP, 1999) | 0.3 |
| "Environmental exposures to tri-cresyl phosphates (TCPs) and the possible formation of toxic metabolites (e." | ( Assessment of neurotoxic effects of tri-cresyl phosphates (TCPs) and cresyl saligenin phosphate (CBDP) using a combination of in vitro techniques. Hausherr, V; Liebing, J; Schöbel, N; van Thriel, C, 2017) | 0.46 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " These findings together with the observations that the PEGylated rHuAChE exhibits unaltered biodistribution and high bioavailability present a case for using PEGylated rHuAChE as a very efficacious bioscavenger of OP agents." | ( Comparison of polyethylene glycol-conjugated recombinant human acetylcholinesterase and serum human butyrylcholinesterase as bioscavengers of organophosphate compounds. Cohen, O; Kronman, C; Mazor, O; Ordentlich, A; Raveh, L; Shafferman, A, 2006) | 0.33 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Histologically, highly variable spinal cord damage was recorded throughout treatment groups and mean damage scores followed a dose-response pattern with no apparent correlation to threshold (i." | ( Murine susceptibility to organophosphorus-induced delayed neuropathy (OPIDN). Blackmon, K; Padilla, S; Pope, C; Veronesi, B, 1991) | 0.28 |
| "Previous studies have shown that after dosing with tri-o-cresyl phosphate (TOCP), the testis contains more active intermediate (saligenin cyclic-o-tolyl phosphate; SCOTP) than do other organs or blood." | ( The interaction of Sertoli and Leydig cells in the testicular toxicity of tri-o-cresyl phosphate. Burka, LT; Chapin, RE; Heindel, JJ; Phelps, JL; Somkuti, SG, 1990) | 0.28 |
| "The dose-response (0." | ( The effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase and carboxylesterase activities of the rat. Jimmerson, VR; Kaminskis, A; Mailman, RB; Maxwell, DM; Shih, TM, 1989) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 11 (28.21) | 18.7374 |
| 1990's | 13 (33.33) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 10 (25.64) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 40 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||